Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840810 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL10241493 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14763943 | 0.87 | CYP3A4 (0.44) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL19797953 | 0.87 | CYP3A4 (0.50) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL18038582 | 0.86 | MEN1 (0.52) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL17464359 | 0.86 | CYP3A4 (0.45) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2840803 | 0.85 | CYP3A4 (0.45) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2839079 | 0.85 | CYP3A4 (0.47) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2841597 | 0.84 | CYP3A4 (0.44) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 | |
| SCHEMBL4304092 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP2C8CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4537315-B2 | — | — | 2010-09-01 | — | — | JP | claimed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | claimed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | claimed |
| JP-2006510736-A | — | — | 2006-03-30 | — | — | JP | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| US-20180099953-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016133963-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133972-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133970-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | CYP3A4 38/4885CYP2C8 27/4885CYP2C9 129/4885 |
| US-20180099953-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | EIF2AK2, UGT2B7, TMBIM6 | CYP3A4 107/4885CYP2C8 44/4885CYP2C9 94/4885 |
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | ZC3HAV1, TMBIM6, EIF2AK2 | CYP3A4 159/4885CYP2C8 64/4885CYP2C9 172/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | CYP3A4 38/4885CYP2C8 27/4885CYP2C9 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.